Basic Plaquenil Information

• INN (International Nonproprietary Name): Hydroxychloroquine
• Brand Names Available In United Kingdom: Plaquenil; Hydroxychloroquine Sulfate (generic equivalents commonly dispensed in the UK); Hydroxychloroquine Winthrop may appear as a European equivalent.
• ATC Code: P01BA02
• Forms & Dosages: Film-coated tablets 200 mg are the most common strength, usually supplied in blister packs of 30 or 60 tablets; 100 mg tablets are rare and mainly seen in some international markets.
• Manufacturers In United Kingdom: Sanofi (Plaquenil) is the principal originator brand; multiple generic manufacturers supply hydroxychloroquine sulfate to UK pharmacies post-pandemic.
• Registration Status In United Kingdom: Prescription only (Rx) and authorised for indicated uses by national regulators; generics are widely available.
• OTC / Rx Classification: Prescription (Rx) only

Latest Research Highlights

Is hydroxychloroquine still useful for COVID or better saved for autoimmune disease?

Large randomised controlled trials in the UK and across the EU from 2022 to mid‑2024 reaffirmed that hydroxychloroquine provides negligible clinical benefit for COVID‑19 treatment or prevention.

Meta‑analyses pooling those RCTs also showed no meaningful reduction in hospitalisation or mortality for patients treated with hydroxychloroquine in acute viral settings.

Regulatory and professional bodies issued advisories limiting its use in acute viral illness due to lack of efficacy and measurable cardiac risk when combined with QT‑prolonging agents.

By contrast, observational cohorts and registry data collected across NHS trusts and European lupus clinics continue to show sustained benefit for systemic lupus erythematosus.

These autoimmune datasets reported fewer SLE flares, reduced corticosteroid requirements and better skin disease control in patients maintained on hydroxychloroquine.

Rheumatoid arthritis registries indicate modest disease‑modifying activity when hydroxychloroquine is used as part of a DMARD regimen rather than as monotherapy for severe disease.

Safety monitoring emphasised retinal toxicity as a cumulative‑dose signal and flagged conduction abnormalities in older patients or those on interacting medicines.

MHRA and EMA advisories have urged ophthalmology screening for long‑term users and ECG vigilance where other QT‑prolonging drugs are co‑prescribed.

Safety Data Highlights: retinal toxicity associated with long‑term high cumulative dose and cardiac conduction concern when combined with QT‑prolonging medicines; ongoing Yellow Card reporting supports vigilance.

Clinical Effectiveness In The UK

Will continuing hydroxychloroquine help day‑to‑day symptoms for people with lupus or RA?

NHS rheumatology audits and lupus registries show that hydroxychloroquine remains a standard, evidence‑backed option for SLE and as an adjunctive DMARD for mild–moderate RA.

Clinician‑measured outcomes include fewer documented SLE flares and a measurable reduction in oral corticosteroid prescriptions in long‑term users.

Patient‑reported outcome measures used in UK clinics—pain scores, fatigue scales and validated disease activity indices—often demonstrate modest but meaningful improvements when hydroxychloroquine is continued.

Therapeutic onset is gradual; symptomatic improvement is typically seen within six to twelve weeks for many patients starting therapy for autoimmune indications.

Safety‑driven discontinuation rates reported by NHS services are low, and most stops occur because of ophthalmology concerns or cardiac risk assessment rather than routine intolerance.

For primary care and community nursing, the practical balance is between clinical effectiveness and monitoring logistics.

Initiation is commonly specialist‑led and, once stable, many patients transfer to GP repeat prescribing under shared‑care agreements.

• Objective Measures: reduced flare frequency, lower steroid burden, stable lab markers where relevant.
• Patient‑Reported Measures: less fatigue, improved skin symptoms in discoid lupus, modest pain relief.

Indications And Expanded Uses

What is hydroxychloroquine licensed for in the UK, and when is it used off‑label?

MHRA‑aligned indications in the UK follow EU labels and include treatment and prophylaxis of certain malarias, disease‑modifying therapy in rheumatoid arthritis, and treatment of systemic and discoid lupus.

Off‑label uses are restricted and specialist‑led in UK practice, for example certain dermatological autoimmune cases or selected paediatric rheumatology scenarios with specialist oversight.

During the COVID‑19 pandemic there was widespread interest in off‑label use, but subsequent trial results curtailed routine off‑label prescribing for viral infections.

Malaria prophylaxis and treatment regimens differ markedly from autoimmune dosing and require separate pre‑travel counselling.

1. Prophylaxis Vs Chronic Immunomodulation: Prophylaxis for malaria uses weekly dosing; chronic immunomodulation for RA/SLE uses daily dosing with ongoing monitoring.
2. Monitoring Expectations: baseline ophthalmology for chronic use and periodic reviews; specialist assessment required for off‑label cases.

Composition And Brand Landscape

What is in the tablet and which brands will my pharmacy supply?

The active ingredient is hydroxychloroquine sulfate, with film‑coated 200 mg tablets being the most common presentation in the UK market.

Plaquenil is the historic brand supplied by Sanofi and is typically dispensed as 200 mg film‑coated tablets in blister packs of 30 or 60 tablets.

Generics and alternative brandings are widely available in the UK following post‑pandemic supply changes, and pharmacies commonly dispense generics for cost‑effectiveness.

Common generic manufacturers supplying the market include established multinational and Indian producers; pharmacists check the 200 mg strength and tablet scoring to ensure correct dispensing.

1. INN Vs Brand: INN stands for International Nonproprietary Name (hydroxychloroquine) and helps patients recognise generics versus brand names like Plaquenil.
2. Dispensing Practice: pharmacists may choose branded Plaquenil for continuity or generics for cost savings within NHS formularies.

Contraindications And Special Precautions

Who should not take hydroxychloroquine, and what precautions are necessary?

• Absolute Contraindications: known hypersensitivity to 4‑aminoquinolines and pre‑existing retinopathy; children under about six years require specialist dosing caution.
• Relative Contraindications: cardiac conduction disease, severe hepatic or renal impairment, G6PD deficiency, psoriasis or porphyria, and pregnancy/lactation where specialist assessment is required.

Elderly patients have increased cumulative retinal risk and are more likely to have conduction abnormalities, so baseline ECG and ophthalmology assessment are advisable where interacting medicines are used.

Dosage Guidelines

How is hydroxychloroquine dosed for different uses in NHS practice?

Malaria prophylaxis is commonly 400 mg once weekly, started one to two weeks before travel and continued for four weeks after return.

Malaria treatment regimens frequently use an initial 800 mg dose then 400 mg at 6, 24 and 48 hours as an adult regimen; paediatric doses are weight‑adjusted.

For autoimmune conditions such as RA or SLE typical adult dosing is 200–400 mg daily with many adults on a maximum of approximately 400 mg/day.

Paediatric autoimmune dosing is specialist‑led and weight‑based, commonly in the range of 3–7 mg/kg/day up to a 400 mg ceiling.

Dose adjustments are advised in renal or hepatic impairment and for elderly patients, with ophthalmology monitoring influencing long‑term cumulative dose decisions.

Interactions Overview

What medicines and foods interact with hydroxychloroquine, and how should side effects be reported?

Major drug interactions include additive QT prolongation when combined with macrolide antibiotics such as azithromycin, certain antiarrhythmics and some antidepressants.

Co‑administration with other QT‑prolonging drugs usually requires ECG monitoring or selection of an alternative therapy.

Hydroxychloroquine should not be combined with other 4‑aminoquinolines such as chloroquine.

There are limited CYP450 interactions, but clinicians should remain alert to drugs affecting cardiac conduction.

Food interactions are minimal, so routine timing with meals is at patient preference; advise modest alcohol intake because of potential GI and hepatic effects.

Yellow Card Reporting: The MHRA Yellow Card scheme recorded cardiac and visual adverse events during and after the pandemic and prescribers and patients should report suspected ADRs via Yellow Card.

Cultural Perceptions And Patient Habits

How do UK patients feel about hydroxychloroquine following recent controversy?

Long‑term patients with SLE or RA often view hydroxychloroquine as a trusted chronic therapy because of its steroid‑sparing benefits and tolerability.

The COVID‑19 debate left a legacy of confusion and hesitancy among some patients, driven by early publicity and politicised coverage.

UK patient forums such as Patient.info, and discussion threads on family and condition‑specific sites, show high trust in pharmacist counselling and NHS clinical advice when questions arise.

Many patients rely on GP letters, rheumatology nurse reviews and NHS 111 for practical guidance on monitoring and side‑effect queries.

Community pharmacists at major chains and independent chemists are often the first port of call for everyday questions about packaging, dosing schedules and monitoring reminders.

Common Patient Concerns: risk to vision, interactions with other medicines, clarity about cost and prescription status following pandemic publicity.

Example patient note: “My GP letter recommended an annual eye check after five years, and my pharmacist set up repeat dispensing so I do not run out.”

Availability And Pricing Patterns

Where can patients obtain hydroxychloroquine in the UK, and what will it cost?

Supply across the UK is generally reliable, with Plaquenil and generics stocked by major high‑street chains and NHS‑registered online pharmacies.

Prescriptions are dispensed via NHS prescription or private prescription depending on the clinical route; England retains a per‑item prescription charge for those not exempt.

Scotland, Wales and Northern Ireland typically provide free NHS prescriptions, which creates regional cost differences for patients.

Generics usually reduce the private purchase price and many GPs prescribe generics to meet local formulary cost‑effectiveness requirements.

Post‑pandemic market shifts increased generic availability from multiple manufacturers and wholesalers supplying UK pharmacies.

Note on availability with our service: in our online pharmacy, plaquenil is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Preferences

What are the common alternatives and when are they preferred?

In rheumatology, alternatives include methotrexate, sulfasalazine, leflunomide and biologic agents; choice depends on disease severity, comorbidity and monitoring capacity.

For malaria, artemisinin derivatives are preferred in many regions due to resistance patterns; chloroquine has narrower use because of resistance and a less favourable toxicity profile.

Hydroxychloroquine pros include good tolerability for many patients, oral dosing and steroid‑sparing benefit in SLE.

Main cons are cumulative retinal toxicity risk, interactions with QT‑prolonging drugs and relatively modest efficacy for moderate‑to‑severe RA compared with methotrexate or biologics.

Prescribing preference often follows a simple primary care versus specialist flow: start specialist management for initiation or complex cases, continue stable repeat prescribing in primary care with agreed monitoring triggers.

FAQ

1. Will hydroxychloroquine harm my eyes?

   Long‑term high cumulative doses increase retinal toxicity risk; a baseline ophthalmology assessment and regular screening mitigate that risk.

2. Can I take it with other medicines?

   Tell your GP and pharmacist about all medicines—especially macrolide antibiotics or other QT‑prolonging drugs; some combinations prompt ECG monitoring or a change of therapy.

3. How long until it works?

   Expect weeks to months for benefit when used for autoimmune disease, commonly six to twelve weeks for symptomatic improvement.

4. Is it available on the NHS and what will it cost?

   Hydroxychloroquine is prescription‑only and generally available on the NHS; England applies a per‑item prescription charge unless exempt, while Scotland, Wales and Northern Ireland largely provide free prescriptions.

Guidelines For Proper Use

What should pharmacists say when dispensing hydroxychloroquine and how should patients be supported?

Pharmacists should confirm product strength (200 mg film‑coated tablet), counsel on dosing and missed‑dose guidance—take as soon as remembered but do not double up if the next dose is near.

Advise storage at room temperature (15–30°C) away from moisture and light, and to keep medicines out of reach of children due to overdose risk.

Initiation pathways normally begin under specialist recommendation with baseline ophthalmology and, where indicated, baseline ECG and blood tests for renal and liver function.

Monitoring usually includes ophthalmology screening (baseline, then frequency based on risk factors—often annual after five years but earlier if risks are present) and periodic drug interaction checks.

Pharmacists should provide printed or electronic information leaflets, set up reminders via NHS app or repeat dispensing, and signpost rheumatology nurse helplines and MHRA Yellow Card reporting.

• Pharmacist Counselling Checklist: confirm strength and dosing, review current medicines for interactions, advise on eye‑symptom vigilance, and arrange monitoring reminders.
• Patient One‑Page Leaflet Template: name of medicine, dose, when to seek urgent care (vision changes, chest pain, palpitations), storage, and contact details for GP and pharmacy.

Delivery Across United Kingdom